Effect of intravenous immunoglobulin in immune thrombocytopenia.
The rapid rise in platelet count after immunoglobulin treatment in acute and chronic forms of idiopathic thrombocytopenic purpura (ITP), autoimmune neutropenia, and post-transfusion purpura is well documented. It is suggested that the rise in platelet count is due to competitive inhibition of the macrophage binding of platelets by preferential sequestration of immunoglobulin-coated red blood cells. Measurement of haptoglobin levels, a sensitive indicator of haemolysis, suggests that clinically inapparent haemolysis occurs during immunoglobulin therapy of ITP patients. In-vitro experiments confirm that there is immunoglobulin coating of red blood cells. The hypothesis is further supported by the findings that immunoglobulin treatment in autoimmune haemolytic anaemia is ineffective, and that platelet counts rise in some ITP patients after induction of a mild haemolytic syndrome by injection of anti-Rho (D).
D000293:Adolescent; D000328:Adult; D000743:Anemia, Hemolytic / Q000628:therapy; D004912:Erythrocytes / Q000276:immunology*; D006461:Hemolysis; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007275:Injections, Intravenous; D007518:Isoantibodies / Q000276:immunology; D008264:Macrophages / Q000276:immunology*; D008875:Middle Aged; D011696:Purpura, Thrombocytopenic / Q000276:immunology / Q000628:therapy*; D012204:Rh-Hr Blood-Group System / Q000276:immunology
D007074:Immunoglobulin G; D007518:Isoantibodies; D012204:Rh-Hr Blood-Group System